June/Juin 2015

Nous sommes heureux de vous annoncer qu’après 10 mois d’existence, l’équipe d’HCS Pharma se constitue avec l’arrivée de nouvelles personnes, comme Meryl Roudaut, portant l’équipe à 6 personnes. Vous trouverez ci-dessous la présentation de Meryl arrivé en mars. Nous vous présenterons prochainement les autres personnes nouvellement arrivées et les nouveaux développements cellulaires.

We are happy to announce that after 10 months of existence, the team of HCS Pharma expanded up to 6 members, with the arrival of new people like Meryl Roudaut in March. You will find below his presentation. We will present you soon the other newcomers and new cell assay development.

Meryl joins us to work on genotoxicity evaluations

After a license degree in Cellular Biology and physiology (“Biologie Cellulaire et Physiologie”) and a first year of master degree in toxicology (“Evaluation des risques toxicologique pour le consommateur”) at Université de Bretagne occidentale (UBO), Méryl Roudaut is currently studying for his second year of master degree at Université Paul Sabatier (UPS) Toulouse III (“Biologie intégrative et Toxicologie”). He joined HCS Pharma as an intern for 6 months to work on in vitro models to evaluate genotoxicity.

Automated Video-Based Analysis of Contractility in Cardiomyocytes

Cardiotoxicity analysis of compund is often performed in a later phase during developement. Now, with cell imaging, cardiotoxicity assay can be performed in vitro in higher throughput and thus this assay can be used in the early phase of research. In this article, they explained how to do the automation in an unbiased way the Video-Based Analysis of Contractility and Calcium Flux of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Cultures.

Single-Cell Genomics Allows Identification of New Cell Types

Aviv Regev at the Broad Institute, in Cambridge, uses fluidic systems to separate cells and submits them to detailed genetic analysis, at the rate of thousands per day. The goal is to build a comprehensive cellular human atlas, based on gene expression profiling.
 

Interview of Steve Rees, of AstraZeneca, on cutting-edge Technologies for Drug Target Validation

This is an interesting summary of the strategy adopted by pharmaceutical industry presented by Steve Rees, the Vice-President of screening sciences and sample management at Aztrazeneca. This interview was realised by selectscince last month.

Identification of potential therapeutic target by phenotypic screening for proteinuric kidney diseases

Last week, we were very pleased to meet the french team for Dell worldwide program "Center for Entrepreneurs". After useful discussions about data management, data storage, visualisation and data maining, we improved our picture's workflows and we imagined many new and innovative ways to develop ! The « Speed Mentoring » with Dell's experts was very effective.

Services

Explain us your requirements and we develop your assays to best meet your needs !

Our vision

To target complex diseases (as cancer and neurodegenerative diseases), more than one target are needed and screening on complex model is recommended.

View this email in your browser
Website
Website
LinkedIn
LinkedIn
Twitter
Twitter
Google Plus
Google Plus
Contact Us
Contact Us
Copyright © 2015 HCS Pharma, All rights reserved.


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp